Policy Notices

• NIH Operates Under a Continuing Resolution
  (NOT-OD-23-052)
  National Institutes of Health
  

General Notices

• Notice of Information: NINDS Extensions for Career Development Award Recipients Whose Career Trajectories Have Been Significantly Impacted by COVID-19
  (NOT-NS-23-043)
  National Institute of Neurological Disorders and Stroke
  

Notice of Changes to Funding Opportunities

• Notice of Pre-Application Webinar for RFA-TR-23-001, "Translational Centers for Microphysiological Systems (TraCe MPS) (U2C Clinical Trials Not Allowed)"
  (NOT-AG-22-043)
  National Institute on Aging
  

• Notice of Formatting Changes to PAR-22-047, "Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)"
  (NOT-AG-22-050)
  National Institute on Aging
  

• Notice of Change to PAR-22-114, Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)
  (NOT-CA-23-029)
  National Cancer Institute
  

• Notice of Correction to Eligibility Criteria for PAR-21-315 "Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)"
  (NOT-NS-23-056)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Corrections to PAR-23-045 Biomedical Research Facilities (C06 Clinical Trial Not Allowed)
  (NOT-OD-23-051)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  

Requests for Proposal

• Notice of Proposed Contract Action (Presolicitation) for Request for Proposals (RFP) Solicitation 75N91023R00024: PREVENT Cancer Preclinical Drug Development Program
  (NOT-CA-23-028)
  National Cancer Institute
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Administrative Supplements to NIH Centers for AIDS Research (CFAR) and NIMH AIDS Research Centers (ARC) for Ending the HIV Epidemic (EHE)
  (NOT-AI-23-016)
  National Institute of Allergy and Infectious Diseases
  National Institute of Mental Health
  

• Notice of Special Interest (NOSI): Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases
  (NOT-AR-23-008)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  

• Notice of Special Interest (NOSI): Administrative Supplement to Support Global Cancer Stigma Research
  (NOT-CA-23-025)
  National Cancer Institute
  

Funding Opportunities

• NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)
  (PAR-23-049)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 17, 2025
  
  

• Limited Competition: Brain Tissue Resource Center for Alcohol Research (R28 Clinical Trial Not Allowed)
  (PAR-23-068)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): March 14, 2023
  
  

• NIAMS Skin Biology and Diseases Resource-based Centers (P30 - Clinical Trial Not Allowed)
  (RFA-AR-24-001)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): May 18, 2023
  
  

• NIAMS Resource-based Centers for Bone, Muscle and Orthopaedic Research (P30 - Clinical Trial Not Allowed)
  (RFA-AR-24-002)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): May 18, 2023
  
  

• AHRQ and PCORI Learning Health System Embedded Scientist Training and Research Centers (P30)
  (RFA-HS-23-001)
  Agency for Healthcare Research and Quality
  Application Receipt Date(s): March 24, 2023. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R01 Clinical Trial Optional)
  (RFA-MH-23-115)
  National Institute of Mental Health
  Application Receipt Date(s): March 24, 2023
  
  

• Bidirectional Influences Between Adolescent Social Media Use and Mental Health (R21 Clinical Trial Optional)
  (RFA-MH-23-116)
  National Institute of Mental Health
  Application Receipt Date(s): March 24, 2023
  
  

• Translational Centers for Microphysiological Systems (TraCe MPS) (U2C Clinical Trials Not Allowed)
  (RFA-TR-23-001)
  National Center for Advancing Translational Sciences
  National Cancer Institute
  National Institute on Aging
  Application Receipt Date(s): March 27, 2023